Table 3. The most common drugs with a potential DDI among HCV-infected patients with moderate-to-severe liver disease.
| Drug | N. Patients (%) | DAA Regiments with Possible Category 2 DDIs |
|---|---|---|
| PPI | 124 (34.2) | SOF/LDV; 3D |
| Propranolol | 70 (19.5) | 3D |
| Furosemide | 56 (15.4) | 3D |
| Levothyroxin | 30 (8.2) | SOF/DCV; 3D |
| Lactulose | 26 (7.1) | 3D |
| UDCA | 26 (7.1) | SOF; SOF/SIM; SOF/DCV; SOF/LDV |
| Amlodipin | 24 (6.6) | SOF/SIM; SOF/DCV; SOF/LDV; 3D |
| Carvedilol*§ | 18 (5) | SOF; SOF/SIM; SOF/DCV; SOF/LDV; 3D |
| Rifaximin | 18 (4.9) | 3D |
| Irbesartan | 15 (4.1) | SOF/LDV; 3D |
| Prednisone | 14 (3.8) | SOF/SIM; 3D |
| Alpraxolam | 12 (3.3) | 3D |
| Olmesartan*§ | 12 (3.3) | SOF; SOF/SIM; SOF/LDV; 3D |
| Bisoprolol | 11 (3) | SOF; SOF/SIM; SOF/LDV; 3D |
| Sertralin§ | 8 (2.2) | SOF; SOF/SIM; SOF/DCV; 3D |
| Telmisartan | 8 (2.2) | 3D |
| Allopurinolo | 7 (1.9) | SOF; SOF/SIM; SOF/DCV; SOF/LDV |
| Doxazosin§ | 7 (1.9) | SOF; SOF/SIM; SOF/LDV; 3D |
| Enalapril | 7 (1.9) | 3D |
| Valsartan | 7 (1.9) | SOF; SOF/SIM; SOF/DCV; 3D |
| Nebivolol§ | 6 (1.6) | SOF/SIM; SOF/DCV; SOF/LDV |
| Propafenone | 6 (1.7) | SOF/SIM; SOF/LDV; 3D |
| Candesartan§ | 5 (1.1) | SOF; SOF/LDV; 3D |
| Lisinopril | 5 (1.1) | SOF/SIM; SOF/LDV |
| Lormetazepam | 5 (1.1) | 3D |
*Dose adjustment only in the European Summary Product Characteristics. No dosage restrictions in the US prescribing Information.
§ Contraindicated in patients with severe hepatic impairment.